Bartsch H, Petruzzelli S, De Flora S, Hietanen E, Camus A M, Castegnaro M, Geneste O, Camoirano A, Saracci R, Giuntini C
International Agency for Research on Cancer, Lyon, France.
Mutat Res. 1991 Sep-Oct;250(1-2):103-14. doi: 10.1016/0027-5107(91)90167-m.
Individual variations in activity of pulmonary enzymes that metabolize tobacco-derived carcinogens may affect an individual's cancer risk from cigarette smoking. To investigate whether some of these enzymes (e.g., cytochrome P450IA-related) can serve as markers for carcinogen-induced DNA damage accumulating in the lungs of smokers, non-tumorous lung tissue specimens were taken during surgery from middle-aged men with either lung cancer (n = 54) or non-neoplastic lung disease (n = 20). Phase I (AHH, ECDE) and phase II (EH, UDPGT, GST) enzyme activities, glutathione and malondialdehyde contents were determined in lung parenchyma and/or bronchial tissues; some samples were analyzed for DNA adducts, using 32P-postlabeling. Data analysis of subsets or the whole group of patients yielded the following results. (1) Phase I and II drug-metabolizing enzyme (AHH, EH, UDPGT, GST) activities in histologically normal surgical specimens of lung parenchyma were correlated with the respective enzyme activities in bronchial tissues of the same subject. (2) In lung parenchyma, enzyme (AHH, ECDE, EH, UDPGT) activities were significantly and positively related to each other, implying a similar regulatory control of their expression. (3) Mean activities of pulmonary enzymes (AHH, ECDE) were significantly (2- and 7-fold, respectively) higher in lung cancer patients who had smoked within 30 days before surgery (except GST, which was depressed) than in cancer-free subjects with a similar smoking history. (4) In the cancer patients, the time required for AHH, EH and UDPGT activities to return to the level found in non-smoking subjects was several weeks. (5) Bronchial tree and peripheral lung parenchyma preparations exhibited a poor efficiency in activating promutagens to bacterial mutagens in Salmonella. However, they decreased the mutagenicity of several direct-acting mutagens, an effect which was more pronounced in tissue from recent smokers. GSH concentration and GST activity were positively correlated with mutagen inactivation in the same sample. (6) In recent smokers, AHH activity in lung parenchyma was positively correlated with the level of tobacco smoke-derived DNA adducts. (7) Pulmonary AHH and EH activity had prognostic value in tobacco-related lung cancer patients. (8) An enhanced level of pro-oxidant state in the lungs was associated with recent cigarette smoking. Malondialdehyde level in lung parenchyma was associated with the degree of small airway obstruction, suggesting a common free radical-mediated pathway for both lung cancer induction and small airway obstruction.(ABSTRACT TRUNCATED AT 250 WORDS)
代谢烟草衍生致癌物的肺酶活性的个体差异,可能会影响个体因吸烟患癌的风险。为了研究这些酶中的一些(如细胞色素P450IA相关酶)是否可作为吸烟者肺中致癌物诱导的DNA损伤积累的标志物,在手术过程中从患有肺癌(n = 54)或非肿瘤性肺病(n = 20)的中年男性身上获取了非肿瘤性肺组织标本。测定了肺实质和/或支气管组织中的I相(芳烃羟化酶、环氧化物脱氢酶)和II相(环氧化物水解酶、尿苷二磷酸葡糖醛酸基转移酶、谷胱甘肽S-转移酶)酶活性、谷胱甘肽和丙二醛含量;一些样本使用32P后标记法分析了DNA加合物。对部分患者或全部患者进行数据分析,得出以下结果。(1)肺实质组织学正常手术标本中的I相和II相药物代谢酶(芳烃羟化酶、环氧化物水解酶、尿苷二磷酸葡糖醛酸基转移酶、谷胱甘肽S-转移酶)活性,与同一受试者支气管组织中的相应酶活性相关。(2)在肺实质中,酶(芳烃羟化酶、环氧化物脱氢酶、环氧化物水解酶、尿苷二磷酸葡糖醛酸基转移酶)活性彼此之间显著正相关,这意味着它们的表达受到相似的调控。(3)在术前30天内吸烟的肺癌患者中,肺酶(芳烃羟化酶、环氧化物脱氢酶)的平均活性分别显著高于(分别为2倍和7倍)有相似吸烟史的无癌受试者(谷胱甘肽S-转移酶除外,其活性降低)。(4)在癌症患者中,芳烃羟化酶、环氧化物水解酶和尿苷二磷酸葡糖醛酸基转移酶活性恢复到非吸烟受试者水平所需的时间为几周。(5)支气管树和外周肺实质制剂在将前诱变剂激活为沙门氏菌中的细菌诱变剂方面效率较低。然而,它们降低了几种直接作用诱变剂的诱变性,这种作用在近期吸烟者的组织中更为明显。谷胱甘肽浓度和谷胱甘肽S-转移酶活性与同一样本中的诱变剂失活呈正相关。(6)在近期吸烟者中,肺实质中的芳烃羟化酶活性与烟草烟雾衍生的DNA加合物水平呈正相关。(7)肺芳烃羟化酶和环氧化物水解酶活性对烟草相关肺癌患者具有预后价值。(8)肺中促氧化状态的增强与近期吸烟有关。肺实质中的丙二醛水平与小气道阻塞程度有关,这表明肺癌诱导和小气道阻塞存在共同的自由基介导途径。(摘要截短于250字)